586972-84-1

Upstream product

• 586972-83-0 (2R)-2-[(4S)-2,2-dimethyl-5-oxo-1,3-dioxolan-4-yl]-5-(4-ethoxyphenyl)pentanoic acid 
• 771-61-9 2,3,4,5,6-pentafluorophenol 
• 586972-81-8 2R-[3-(4-ethoxy-phenyl)-propyl]-3S-hydroxy-succinic acid diisopropylester 
• 586972-82-9 (2R,3S)-2-[3-(4-ethoxyphenyl)propyl]-3-hydroxybutanedioic acid 

Downstream Products

• 847039-01-4 5-(4-ethoxy-phenyl)-2R-[(2,2-dimethyl-5-oxo-[1,3]dioxolan-4S-yl)]-1-pyrrolidin-1-yl-pentan-1-one 
• 847039-33-2 5-{4-(4-ethoxy-phenyl)-1-[4-(2-fluoro-phenyl)-piperazine-1-carbanoyl]-butyl}-2,2-dimethyl-[1,3]dioxolan-4-one 
• 847039-12-7 5S-{4-(4-ethoxy-phenyl)-1R-[4-(methyl-propyl-amino)-piperidine-1-carbonyl]-butyl}-2,2-dimethyl-[1,3]dioxolan-4-one 

Relevant academic research and scientific papers

DERIVATIVES OF HYDROXAMIC ACID AS METALLOPROTEINASE INHIBITORS

Compounds of formula (I) are inhibitors of matrix metalloproteinases, and are of use in the treatment of, for example fibrotic disease, multiple sclerosis, emphysemia, bronchitis and asthma: formula (I) wherein Ar represents an optionally substituted aryl, heteroaryl, C3-C8 cycloalkyl or heterocycloakyl group; R represents hydrogen or C1-C6 alkyl, or C3-C6 cycloalkyl; Alk represents a divalent C1-C5 alkylene or C2-C5 alkenylene radical; and R1 and R2 taken together with the nitrogen atom to which they are attached form a first heterocycloalkyl ring which is optionally fused to a second C3-C8 cycloalkyl or heterocycloalkyl ring, the said first and second rings being optionally substituted by at least one group of formula (II): formula (II) wherein m, p and n are independently 0 or 1; Z represents, hydrogen, or an optionally substituted carbocyclic or heterocyclic ring of from 5 to 7 ring atoms which is optionally fused to another optionally substituted carbocyclic or heterocyclic ring of from 5 to 7 ring atoms; Alk1 and Alk2 independently represent optionally substituted divalent C1-C3 alkylene radicals; X represents -0-, -S-, -S(O)-, -S(O2)-, -C(=O)-, -NH-, -NR3-, -S(O2)NH-, -S(O2)NR3-, -NHS(O2)-, or -NR3S(O2)-, where R3 is C1-C3 alkyl.

METALLOPROTEINASE INHIBITORS

Compounds formula (IA) or (IB); wherein W represents HO(C=0)-, HONH(C=0)- or H(C=O)N(OH)-; X represents -O- or -S-; and R1, R2, and R3 are as defined in the description and claims, are inhibitors of matrix metalloproteinases, in particular MMP9 and/or MMP12.